Trial Profile
A retrospective study to evaluate the efficacy and toxicity of ipilimumab in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 May 2016 New trial record
- 28 Apr 2016 Efficacy and toxicity results (n=40) published in the British Journal of Cancer.